Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.56 |
| ▸ | TUBB | P07437 | 2/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.56 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.56 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.56 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28244199 | 0.98 | MEN1 (0.58) | KDM4EGAANR4A2TUBB4ATUBB | |
| Benzyl Alcohol SCHEMBL28588964 | 0.89 | KDM4E (0.51) | KDM4EGAANR4A2TUBB4ATUBB | |
| SCHEMBL22746578 | 0.86 | KDM4E (0.59) | KDM4EGAANR4A2TUBB4ATUBB | |
| SCHEMBL9986684 | 0.84 | HPGD (0.57) | KDM4EGAANR4A2TUBB4ATUBB | |
| SCHEMBL9986687 | 0.84 | HPGD (0.57) | KDM4EGAANR4A2TUBB4ATUBB | |
| SCHEMBL3198815 | 0.84 | ALOX15 (0.68) | KDM4EGAATUBB4ATUBBTUBA3C | |
| SCHEMBL29643083 | 0.84 | GABRA1 (0.49) | KDM4EGAANR4A2TUBB4ATUBB | |
| SCHEMBL9215592 | 0.84 | GABRA1 (0.49) | KDM4EGAANR4A2TUBB4ATUBB | |
| SCHEMBL2227263 | 0.82 | KDM4E (0.46) | KDM4EGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1253813 | 0.81 | EGFR (0.50) | KDM4EGAANR4A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121527-B | Tricyclic compounds and uses thereof | 上海辉启生物医药科技有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| WO-2021143816-A1 | FUSED IMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| CN-113121527-A | Tricyclic compound and use thereof | 上海辉启生物医药科技有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-9475831-B2 | Formylpyrrole-based heterocycles for nucleic acid attachment to supports | ILLUMINA, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160137677-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | ILLUMINA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9273074-B2 | Formylpyrrole-based heterocycles for nucleic acid attachment to supports | ILLUMINA, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | KDM4E 3244/4885GAA 426/4885NR4A2 179/4885 |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | KDM4E 3244/4885GAA 426/4885NR4A2 179/4885 |
| US-20160137677-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | CCNY, FBL, NSUN2 | KDM4E 2199/4885GAA 4272/4885NR4A2 174/4885 |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | KDM4E 3353/4885GAA 3908/4885NR4A2 123/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | KDM4E 3353/4885GAA 3908/4885NR4A2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.